Literature DB >> 29722820

Leishmania (Viannia) guyanensis in tegumentary leishmaniasis.

Arissa Felipe Borges1, Rodrigo Saar Gomes1, Fátima Ribeiro-Dias1.   

Abstract

Leishmania (Viannia) guyanensis is a causal agent of American tegumentary leishmaniasis (ATL). This protozoan has been poorly investigated; however, it can cause different clinical forms of ATL, ranging from a single cutaneous lesion to severe lesions that can lead to destruction of the nasopharyngeal mucosa. L. (V.) guyanensis and the disease caused by this species can present unique aspects revealing the need to better characterize this parasite species to improve our knowledge of the immunopathological mechanisms and treatment options for ATL. The mechanisms by which some patients develop a more severe form of ATL remain unclear. It is known that the host immune profile and parasite factors may influence the clinical manifestations of the disease. Besides intrinsic parasite factors, Leishmaniavirus RNA 1 (LRV1) infecting L. guyanensis can contribute to ATL immunopathogenesis. In this review, general aspects of L. guyanensis infection in humans and mouse models are presented.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29722820     DOI: 10.1093/femspd/fty025

Source DB:  PubMed          Journal:  Pathog Dis        ISSN: 2049-632X            Impact factor:   3.166


  6 in total

1.  Leishmania guyanensis M4147 as a new LRV1-bearing model parasite: Phosphatidate phosphatase 2-like protein controls cell cycle progression and intracellular lipid content.

Authors:  Alexandra Zakharova; Amanda T S Albanaz; Fred R Opperdoes; Ingrid Škodová-Sveráková; Diana Zagirova; Andreu Saura; Lˇubomíra Chmelová; Evgeny S Gerasimov; Tereza Leštinová; Tomáš Bečvář; Jovana Sádlová; Petr Volf; Julius Lukeš; Anton Horváth; Anzhelika Butenko; Vyacheslav Yurchenko
Journal:  PLoS Negl Trop Dis       Date:  2022-06-24

2.  A Mouse Model of Ulcerative Cutaneous Leishmaniasis by Leishmania (Viannia) panamensis to Investigate Infection, Pathogenesis, Immunity, and Therapeutics.

Authors:  Natalia Muñoz-Durango; Alexander Gómez; Natalia García-Valencia; Miguel Roldán; Marcela Ochoa; David E Bautista-Erazo; José R Ramírez-Pineda
Journal:  Front Microbiol       Date:  2022-06-13       Impact factor: 6.064

3.  Virtual Screening and the In Vitro Assessment of the Antileishmanial Activity of Lignans.

Authors:  Mayara Dos Santos Maia; Joanda Paolla Raimundo E Silva; Thaís Amanda de Lima Nunes; Julyanne Maria Saraiva de Sousa; Gabriela Cristina Soares Rodrigues; Alex France Messias Monteiro; Josean Fechine Tavares; Klinger Antonio da Franca Rodrigues; Francisco Jaime B Mendonça-Junior; Luciana Scotti; Marcus Tullius Scotti
Journal:  Molecules       Date:  2020-05-12       Impact factor: 4.411

4.  Diagnostic accuracy of Enzyme-Linked Immunosorbent Assays to detect anti-Leishmania antibodies in patients with American Tegumentary Leishmaniasis: a systematic review.

Authors:  Andernice Dos Santos Zanetti; Camila Massae Sato; Fabiana Gulin Longhi; Silvana Margarida Benevides Ferreira; Omar Ariel Espinosa
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2019-08-19       Impact factor: 1.846

Review 5.  Cutaneous Leishmaniasis: The Complexity of Host's Effective Immune Response against a Polymorphic Parasitic Disease.

Authors:  Áurea Gabriel; Ana Valério-Bolas; Joana Palma-Marques; Patrícia Mourata-Gonçalves; Pedro Ruas; Tatiana Dias-Guerreiro; Gabriela Santos-Gomes
Journal:  J Immunol Res       Date:  2019-12-01       Impact factor: 4.818

6.  Mucocutaneous Leishmaniasis in a Pregnant Immigrant.

Authors:  Neima Briggs; Brian M Wei; Chaarushi Ahuja; Catherine Baker; Carlo Foppiano Palacios; Emily Lee; Niamh O'Grady; Santhi Singanamala; Katelyn Singh; Thilinie D Bandaranayake; Jeffrey M Cohen; William Damsky; Matthew W Davis; Rojelio Mejia; Caroline A Nelson; Jeffrey E Topal; Marwan M Azar
Journal:  Open Forum Infect Dis       Date:  2022-07-22       Impact factor: 4.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.